- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00365599
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer Who Have Failed Prior Anti-hormonal Therapy.
연구 개요
상태
정황
상세 설명
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined. Tamoxifen will be given once daily, continuously. Vorinostat will be given daily for 3 out of 4 weeks (a cycle). Responses will be assessed (restaged) after 2 cycles and toxicities will be captured continuously. Eligible patients will receive treatment in consecutive 4-week cycles, until progression of disease or unacceptable toxicity. Patients will be followed for evaluation of safety for at least 30 days after the last dose of the study drug.
Tests will be obtained pre-and post vorinostat treatment and correlated with plasma levels of vorinostat at the time of tumor biopsy and vorinostat doses; the tests will consist of:
- Patient history
- Physical exam (including height and weight)
- Toxicity assessment
- Pharmacokinetic (PK) sample
- Tumor fine needle aspirate (FNA)
- Peripheral Blood Mononuclear Cells (PBMC)
- Standard labs and Chemistry Profile
- Carcinoembryonic antigen (CEA), cancer antigen (Ca) 15-3, Ca 125 (If clinically indicated)
- Pregnancy Test
- Computed tomography (CT) scans, and magnetic resonance imaging (MRI)
Documentation of response and progression will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST).
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
San Francisco, California, 미국, 94143
- University of California
-
-
Florida
-
Boynton Beach, Florida, 미국, 33435
- Bethesda Memorial Hospital Research Center
-
Orlando, Florida, 미국, 32806
- M.D. Anderson of Orlando
-
Port Charlotte, Florida, 미국, 33949
- Fawcett Memorial Hospital
-
Stuart, Florida, 미국, 34994
- Martin Memorial Cancer Center
-
Tallahassee, Florida, 미국, 32308
- Tallahassee Memorial Healthcare, Inc.
-
Tampa, Florida, 미국, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Georgia
-
Savannah, Georgia, 미국, 31405
- St. Joseph's/Candler
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patients must have cytologically/histologically documented locally advanced or metastatic breast cancer with either:
- Progression on treatment with any aromatase inhibitor for metastatic disease;
- Recurrence while on adjuvant aromatase inhibitors or within 12 months of completion;
- Recurrence after having completed adjuvant tamoxifen for at least 12 months;
- Patient who are not candidates for or are intolerant of aromatase inhibitor treatment;
- Patients are allowed (but not required) to have one prior chemotherapy regimen for metastatic disease.
- Tumors must express estrogen or progesterone receptor.
- Patients are eligible regardless of the menopausal status.
- Age > 18 years old
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Patients must be able to give informed consent and able to follow guidelines given in the study.
- Patients must have acceptable organ function, as defined by the following laboratory parameters: white blood count (WBC) >3.0 x 10^9/L; absolute neutrophil count (ANC) >1.5 x 10^9/L; hemoglobin (Hgb) >10.0g/dL; platelets (PLT) >100 x 10^9/L, Bilirubin < 2.0 mg/dl, aspartate aminotransferase/alanine aminotransferase (AST/ALT) < 2.5 X upper limit of normal (ULN), Creatinine <1.8 mg/dl (Creatinine clearance >60 ml/min).
- Women of childbearing age must have a negative pregnancy test. All patients of reproductive potential must use an effective method of contraception during the study and 6 months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year.
- Patients must have measurable disease by RECIST criteria by staging studies performed within 30 days of enrollment. For patients with bone only disease: For this protocol isolated bone lesions can be classified as target lesions if they are measurable by MRI at screening and must be followed by MRI.
- Both men and women of all races and ethnic groups are eligible for this trial.
Exclusion Criteria:
- Patients must not have received tamoxifen for metastatic disease.
- Patients must not have evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.
- Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of: curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix.
- Pregnant and breast-feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.
- Patients with uncontrolled central nervous system (CNS) metastasis or a history of seizures are excluded. Patients with stable CNS metastasis (either surgically resected, treated with gamma knife or stable for 3 months following whole brain radiation therapy [WBRT] are eligible). Patients with stable brain metastases will need an MRI within 4 weeks prior to start of therapy.
- Patients may not be receiving any other investigational agents and must have stopped all other histone deacetylase inhibitors (including Valproic acid) or other hormonal therapies.
- Patients must have discontinued their prior therapies for breast cancer and radiation therapy for a minimum of 3 weeks, patient is excluded if radiation therapy was given to a single measurable lesion and the disease is otherwise not measurable.
- Patients are excluded if they have any known hypersensitivity reaction to tamoxifen.
- Patient with a history of blood clots are not eligible.
- Women who have abnormal vaginal bleeding and/or endometrial hyperplasia or cancer are not eligible.
- Patients with evidence of visceral crisis are not eligible for this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Vorinostat and Tamoxifen
As outlined in Intervention descriptions
|
Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance.
All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks.
Responses will be assessed after 2 cycles (8 weeks + 4 days).
다른 이름들:
Tamoxifen will be given once daily at 20 mg.
Tamoxifen will be given continuously.
Responses will be assessed after 2 cycles (8 weeks + 4 days).
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Objective Response (OR)
기간: 24 weeks
|
The Objective Response Rate.
Response and progression were evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria.
For the purposes of this study, patients were evaluated for response every 8 weeks.
In addition to a baseline scan, confirmatory scans were also obtained ≥ 4 weeks following initial documentation of objective response.
|
24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Time to Progression (TTP)
기간: Up to 30 months
|
The median response duration in months.
Response and progression were evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).
|
Up to 30 months
|
Number of Participants With Serious Adverse Events (SAEs)
기간: 4 years, 7 months
|
Safety evaluation according to descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
|
4 years, 7 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Susan Minton, D.O., H. Lee Moffitt Cancer Center and Research Institute
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- MCC-14662
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
suberoylanilide hydroxamic acid (SAHA, Vorinostat)에 대한 임상 시험
-
Merck Sharp & Dohme LLC완전한균상 식육종 | 시자리 증후군 | 피부 T 세포 림프종
-
Merck Sharp & Dohme LLC종료됨
-
Merck Sharp & Dohme LLC종료됨